Akari Therapeutics, Plc (AKTX) Fair Value 2026

AKTX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.1 /10

32 fundamental signals · 1 models active

Value Trap Risk

DANGER (70/100)

Quick Summary — As of 2026-08-28, Akari Therapeutics, Plc (AKTX) trades at $10.70. QOC: 4.1/10. Value Trap Risk: 70/100 (DANGER). 1/13 models active.

Key Facts

Ticker
AKTX
Price
$10.70
Quality Score
4.1/10
Value Trap Risk
70/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 70 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give AKTX?

1 Intrinsic Value Models vs. Current Price ($10.70)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $3.13 -70.7%

All Models Active

All 1 models are displayed above.

What Is Akari Therapeutics, Plc (AKTX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Akari Therapeutics, Plc's intrinsic value is estimated at $3.13. Trading at its current price of $10.70, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -70.7%.

What Do the Models Say About AKTX?

1 of 13 models are currently active for AKTX. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does AKTX Rank in Biotechnology?

Among 625 Biotechnology stocks, AKTX ranks #516 by Quality of Company score. CirclFi's QOC score of 4.1/10 evaluates 32 fundamental signals. A score of 4.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotech businesses. For Akari Therapeutics, Plc, metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is AKTX a Value Trap?

CirclFi's Value Trap algorithm assigns AKTX a score of 70/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Akari Therapeutics, Plc. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Akari Therapeutics, Plc scores 4.1 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones. The elevated Value Trap score, however, warrants additional due diligence.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every AKTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across AKTX's 1 active models, average confidence is 56%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Akari Therapeutics, Plc Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CNTNCanton Strategic Holdings, Inc.QOC 4.2ARMPArmata Pharmaceuticals, Inc.QOC 4.1RNTXRein Therapeutics Inc.QOC 4.2GTBPGT Biopharma, Inc.QOC 4.1HUMAHumacyte, Inc.QOC 4.2TVRDTvardi Therapeutics, Inc.QOC 4.1MGTXMeiraGTx Holdings plcQOC 7.0ACETAdicet Bio, Inc.QOC 5.6MPLTMapLight Therapeutics, Inc.QOC 4.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CNTN · ARMP · RNTX · GTBP · HUMA · TVRD · MGTX · ACET · MPLT · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to AKTX?

7 companies across all industries closest to AKTX’s Quality of Company score of 4.1/10.

RIMEAlgorhythm Holdings, Inc.QOC 4.1CONCConectiSys CorporationQOC 4.1CSUICannabis Suisse Corp.QOC 4.1RAINRain Enhancement Technologies Holdco, Inc.QOC 4.1CSBACSBAQOC 4.2IMOImperial Oil LimitedQOC 4.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RIME · CONC · CSUI · RAIN · CSBA · IMO · NVDA

Where Does AKTX Sit in CirclFi's Biotechnology Rankings?

AKTX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Akari Therapeutics, Plc’s Valuation?

What is Akari Therapeutics, Plc's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Akari Therapeutics, Plc (AKTX). The Quality of Company score is 4.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is AKTX overvalued or undervalued right now?

At $10.70, 0 of 1 active models suggest AKTX may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Akari Therapeutics, Plc's business model in Biotechnology.

What does a Quality of Company score of 4.1 mean for AKTX?

Akari Therapeutics, Plc's QOC of 4.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on AKTX?

CirclFi analyzes AKTX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is AKTX a value trap in 2026?

Akari Therapeutics, Plc's Value Trap score is 70/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Akari Therapeutics, Plc (AKTX) a Quality of Company score of 4.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/AKTX/ · Methodology
Primary sources for this AKTX valuation
  • Financial statements: Akari Therapeutics, Plc 10-K and 10-Q filings on SEC EDGAR (CIK 0001541157) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for AKTX as of ; valuations recomputed .